Literature DB >> 9192989

High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours.

E Venetsanakos1, I Beckman, J Bradley, J M Skinner.   

Abstract

Despite the presence of a lymphocytic infiltrate in solid cancers, the failure for tumour growth to be contained suggests an inadequate immune response to the tumour. Poor cytotoxicity exerted by tumour-infiltrating lymphocytes (TILs) against tumour cells in vitro, combined with continued tumour growth in vivo, suggests deficiencies in TIL function or numbers. Various theories have been postulated to explain how tumour cells may escape immunosurveillance and control. One of the many hypotheses is the failure of production of cytokines, which are necessary for T cells to mediate their function. Thus, the expression of cytokine mRNA in human breast tumour sections was investigated by reverse transcriptase polymerase chain reaction (RT-PCR) with cytokine-specific primers. A relatively consistent finding was detection of interleukin (IL) 10 mRNA among the tumours. No IL-2 and little IL-4 mRNA was detected in the tumours. IL-6 and IL-10 mRNA was detected in only one and two of the normal breast tissues respectively. IL-2, IL-4 and tumour necrosis factor (TNF)-alpha mRNA was not detected in any of the normal breast tissues. The reduced function of TILs may be related to IL-10, which has known inhibitory effects on T-cell activation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192989      PMCID: PMC2223600          DOI: 10.1038/bjc.1997.311

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients.

Authors:  P Whitford; W D George; A M Campbell
Journal:  Cancer Lett       Date:  1992-01-10       Impact factor: 8.679

2.  IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.

Authors:  L Ding; P S Linsley; L Y Huang; R N Germain; E M Shevach
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

3.  Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.

Authors:  R de Waal Malefyt; H Yssel; J E de Vries
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

4.  Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma.

Authors:  J C Becker; T Brabletz; C Czerny; C Termeer; E B Bröcker
Journal:  Int Immunol       Date:  1993-12       Impact factor: 4.823

5.  Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance.

Authors:  A H Enk; V L Angeloni; M C Udey; S I Katz
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

6.  Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns.

Authors:  A Merlo; A Juretic; M Zuber; L Filgueira; U Lüscher; V Caetano; J Ulrich; O Gratzl; M Heberer; G C Spagnoli
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

7.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer.

Authors:  Y Chin; J Janseens; J Vandepitte; J Vandenbrande; L Opdebeek; J Raus
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

8.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

9.  Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.

Authors:  G A Gastl; J S Abrams; D M Nanus; R Oosterkamp; J Silver; F Liu; M Chen; A P Albino; N H Bander
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

10.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  21 in total

Review 1.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Hypermethylation of IFN-γ in oral cancer tissues.

Authors:  Songbo Tian; Chunyang Jiang; Xiaoqin Liu; Sheng Xu; Zhiyong Zhang; Huizhen Chen; Yinghuai Zhang; Yanping Liu; Dong Ma
Journal:  Clin Oral Investig       Date:  2017-01-13       Impact factor: 3.573

Review 3.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 4.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

5.  Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.

Authors:  Chi-Chen Hong; Song Yao; Susan E McCann; Ree Y Dolnick; Paul K Wallace; Zhihong Gong; Lei Quan; Kelvin P Lee; Sharon S Evans; Elizabeth A Repasky; Stephen B Edge; Christine B Ambrosone
Journal:  Breast Cancer Res Treat       Date:  2013-04-30       Impact factor: 4.872

6.  A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative.

Authors:  Elnaz Sheikhpour; Parisa Noorbakhsh; Elnaz Foroughi; Soudabeh Farahnak; Rezvan Nasiri; Hossein Neamatzadeh
Journal:  Rep Biochem Mol Biol       Date:  2018-10

Review 7.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Authors:  M Buchert; C J Burns; M Ernst
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

8.  Immune therapy for breast cancer in 2010-hype or hope?

Authors:  A Florescu; E Amir; N Bouganim; M Clemons
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

9.  Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Authors:  Hemanga Kumar Bhattacharjee; Virinder Kumar Bansal; Bikash Nepal; Sandeep Srivastava; Amit K Dinda; Mahesh C Misra
Journal:  Indian J Surg Oncol       Date:  2016-02-20

10.  Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients.

Authors:  Leticia Llanes-Fernández; Maria del Carmen Arango-Prado; Juan Manuel Alcocer-González; Marta Elena Guerra-Yi; Sonia Franco-Odio; Rolando Camacho-Rodríguez; Vicente Madrid-Marina; Reyes Tamez-Guerra; Cristina Rodríguez-Padilla
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.